Desmopressin in moderate hemophilia a patients: A treatment worth considering by Loomans, J.I. (Janneke I.) et al.
550 haematologica | 2018; 103(3)
Received: September 1, 2017.
Accepted: December 27, 2017.
Pre-published: January 5, 2018.
©2018 Ferrata Storti Foundation
Material published in Haematologica is covered by copyright.
All rights are reserved to the Ferrata Storti Foundation. Use of
published material is allowed under the following terms and
conditions: 
https://creativecommons.org/licenses/by-nc/4.0/legalcode. 
Copies of published material are allowed for personal or inter-
nal use. Sharing published material for non-commercial pur-
poses is subject to the following conditions: 
https://creativecommons.org/licenses/by-nc/4.0/legalcode,
sect. 3. Reproducing and sharing published material for com-
mercial purposes is not allowed without permission in writing
from the publisher.
Correspondence: 
c.j.fijnvandraat@amc.uva.nl
Ferrata Storti
Foundation
Haematologica 2018
Volume 103(3):550-557
ARTICLE Coagulation and its Disorders
doi:10.3324/haematol.2017.180059
Check the online version for the most updated
information on this article, online supplements,
and information on authorship & disclosures:
www.haematologica.org/content/103/3/550
Desmopressin increases endogenous factor VIII levels in hemophiliaA. Large inter-individual variation in the response to desmopressinis observed. Patients with a lower baseline factor VIII activity tend
to show a reduced response, therefore, desmopressin is less frequently
used in moderate hemophilia A patients (baseline factor VIII activity 1-5
international units/deciliter), even though factor VIII levels may rise sub-
stantially in some of them. We aim to describe the response to desmo-
pressin in moderate hemophilia A patients and to identify predictors.  We
selected data on 169 patients with moderate hemophilia from the multi-
center Response to DDAVP In non-severe hemophilia A patients: in
Search for dEterminants (RISE) cohort study. Adequate response to
desmopressin was defined as a peak factor VIII level ≥ 30, and excellent
response as ≥ 50 international units/deciliter after desmopressin adminis-
tration. We used univariate and multiple linear regression techniques to
analyze predictors of the peak factor VIII level. Response was considered
adequate in 68 patients (40%), of whom 25 showed excellent response
(15%). Intravenous administration, age, pre-desmopressin factor VIII
activity and von Willebrand factor antigen, peak von Willebrand factor
activity and desmopressin-induced rise in von Willebrand factor antigen
were significant predictors of peak factor VIII level and explained 65% of
the inter-individual variation.  In 40% of moderate hemophilia A patients,
desmopressin response was adequate, thus it is important not to with-
hold this group of patients from desmopressin responsiveness. Among
the six predictors that we identified for desmopressin-induced factor VIII
rise, factor VIII activity and desmopressin-induced rise in von Willebrand
factor antigen had the strongest effect. 
Desmopressin in moderate hemophilia A
patients: a treatment worth considering
Janneke I. Loomans,1 Marieke J.H.A. Kruip,2 Manuel Carcao,3
Shannon Jackson,4 Alice S. van Velzen,1 Marjolein Peters,1
Elena Santagostino,5 Helen Platokouki,6 Erik Beckers,7 Jan Voorberg,8
Johanna G. van der Bom9,10 and Karin Fijnvandraat1,8 for the RISE consortium
1Department of Pediatric Hematology, Immunology and Infectious diseases, 
Emma Children’s Hospital, Amsterdam, the Netherlands; 2Department of Hematology, 
Erasmus University Medical Center, Rotterdam, the Netherlands; 3Division of
Haematology/Oncology, Department of Paediatrics and Child Health Evaluative
Sciences, Research Institute, The Hospital for Sick Children, Toronto, ON, Canada;
4Division of Hematology, Department of Medicine, St. Paul’s Hospital and University 
of British Columbia, Vancouver, BC, Canada; 5A. Bianchi Bonomi Hemophilia and
Thrombosis Center, IRCCS Ca’ Granda Foundation, Maggiore Hospital Policlinico, Milan,
Italy; 6Aghia Sofia Children’s Hospital, Athens, Greece; 7Maastricht University Medical
Centre, the Netherlands; 8Department of Plasma Proteins, Sanquin Research,
Amsterdam, the Netherlands; 9Leiden University Hospital, the Netherlands 
and 10Sanquin Research, Leiden, the Netherlands
ABSTRACT
Introduction 
Hemophilia A (HA) is a hereditary clotting disease caused by mutations in the F8
gene, leading to a deficiency of clotting factor VIII (FVIII) that occurs in one out of
5,000 men. Patients are classified based on residual levels of FVIII activity (FVIII:C).
Severe patients have no detectable FVIII:C, non-severe patients have some activity
(moderate FVIII:C 1-5 and mild 6-40 IU/dL). 
Severe and moderate HA patients are generally treated with FVIII concentrates,
whereas most mild HA patients may be successfully treated with 1-Deamino-8-D-
ArgininVasoPressin (desmopressin; DDAVP) for minor injuries or procedures. Using
DDAVP, and thereby avoiding FVIII concentrates, has two important advantages:
depending on the country, DDAVP is much cheaper than FVIII concentrate, and
DDAVP does not carry the risk of inhibitor development associated with the use of
exogenous (allogeneic) sources of FVIII present in concentrates.1-3
DDAVP is a synthetic vasopressin analogue and can be
administered intravenously, subcutaneously or intranasally.
The drug increases endogenous FVIII plasma concentra-
tions by an average of three- to five-fold by inducing the
release of von Willebrand factor (VWF), the carrier protein
of FVIII, and the direct release of FVIII from Weibel-Palade
bodies (WPBs) in endothelial cells.4,5 FVIII is primarily syn-
thesized in liver sinusoidal endothelial cells.6 Extrahepatic
FVIII is believed to be made by cells in the spleen, by lym-
phatic tissue, and especially by endothelial cells.7-11 The
effect of DDAVP is dependent on the vasopressin type 2
receptor which is highly expressed in lung endothelial cells,
but not in other populations of vascular endothelial cells.12 It
is currently unknown from which sites FVIII and VWF are
released upon DDAVP stimulation. Interestingly, liver trans-
plantation in HA patients eliminates DDAVP response for
FVIII but not for VWF, suggesting that extrahepatic FVIII
synthesis may be necessary for DDAVP response.13
Large inter-individual variation in the response to
DDAVP is observed. The variability of biological response
within the same individual is smaller than between individ-
uals.14 Although the relative increase in VWF and FVIII lev-
els may be similar between non-severe HA patients, as
moderates start at a much lower baseline FVIII:C, they may
not reach a sufficient peak FVIII level to allow for treatment
of minor procedures or trauma. Nevertheless, peak FVIII:C
levels reaching 30 IU/dL may be clinically relevant for
minor procedures or bleeding events. 
Several single-center studies described DDAVP in moder-
ate HA.15-22 A total of 21% of the moderate patients who
were tested showed an increase of FVIII:C to at least 30
IU/dL and identified the following predictors of response:
age, route of administration, blood group, disease severity,
and F8mutations. 
However, these studies were hampered by small sample
sizes and provided heterogeneous outcomes due to differ-
ences in patient characteristics and route of administration.
Moreover, VWF was not studied as a potential determinant
and the outcome variable which was principally studied
was peak FVIII:C. In addition to the peak FVIII:C, the incre-
mental response (proportional rise) may reveal important
information on the biological mechanisms underlying
DDAVP response, with possibly different predictors.
We aim to describe the response to DDAVP in moderate
HA patients and to identify predictors in a large, interna-
tional cohort of moderate HA patients. Our results show
that DDAVP provides a valuable treatment option in a large
proportion of patients with moderate HA.
Methods
Study population
We selected data on all 169 patients with moderate HA from the
multicenter Response to DDAVP In non-severe hemophilia A
patients: in Search for dEterminants (RISE) cohort study, consisting
of 1,474 non-severe HA patients from 24 hemophilia treatment
centers (Figure 1). The aim of the RISE project was to assess the
predictive value of clinical and genetic factors on the DDAVP
response in non-severe HA patients. This international retrospec-
tive cohort study includes all consecutive non-severe HA patients
with DDAVP administration between 1980 and 2012. 
Participating centers (listed in the Online Supplementary Appendix)
were located in Canada, Australia and ten European countries. The
institutional review boards of all centers approved the study. Since
this project involves retrospective data collection, all review boards
indicated that informed consent was not required. This study was
conducted in accordance with the Declaration of Helsinki. 
Data collection 
We collected demographic and clinical data from available med-
ical records using a standardized electronic case report form. The
following data on baseline characteristics were collected: date of
birth, ethnicity, ABO blood group, family history of DDAVP
response, F8mutation (Human Genome Variation Society [HGVS]
numbering was used), reason for DDAVP administration, lifetime
lowest FVIII:C (one-stage clotting assay), pre-DDAVP FVIII:C, pre-
DDAVP VWF antigen (VWF:Ag) and activity (VWF:Act), date of
DDAVP response, DDAVP dose, Body Mass Index (BMI), inhibitor
status, route of administration, FVIII:C/VWF:Ag/VWF:Act after
DDAVP, and potential side effects. In cases where the patient was
treated to prevent or stop bleeding, we also collected information
on the reason for treatment, location and severity of bleeding and
therapeutic response. 
Patient selection
We selected patients from the RISE study with moderate disease
severity. Patients were defined as moderate if one of the available
FVIII:C measurements was 5 IU/dL or lower (lifetime lowest
FVIII:C). In case of multiple DDAVP administrations, we selected
the most recent DDAVP administration. 
It is important to mention that 13 patients from Seary et al. and
17 patients from the study conducted by Stoof et al. with FVIII:C
≤5 IU/dL are also included in our population.15,16 We explored selec-
tion bias of our study population by comparing the RISE popula-
tion to 357 moderate patients from the Intervention as a Goal in
Hypertension Treatment (INternational Study on etiology of
inhibitors in patients with a moderate or mild form of hemophilia
A, influences of Immuno Genetic & Hemophilia Treatment factors
([INSIGHT]) study population that did not receive DDAVP.23 We
compared: FVIII:C, inhibitors, cumulative exposure days to FVIII,
date of birth, and age. 
Definition of response
The main study outcome is the peak FVIII:C after DDAVP (in
IU/dL). We classified peak response as none (<20), partial (20-29),
complete (30-49) or excellent (≥50). With these classifications we
were able to compare our findings to previously reported response
rates. For further univariate analyses of the determinants of
response, we compared patients with inadequate response to
patients with at least a complete response. 
Incremental response was calculated by dividing peak FVIII:C
by pre-DDAVP FVIII:C. Data was collected on the therapeutic
response, which is defined in Online Supplementary Table S1. 
Statistical analyses
Summary statistics include frequencies and percentages for cat-
egorical variables and medians and interquartile ranges for contin-
uous variables. An unpaired t-test and χ2 test were used to compare
means between patients with inadequate response and at least a
complete response. Furthermore, we used multiple linear regres-
sion to model relationships between potential explanatory vari-
ables and peak FVIII:C and incremental response in the patients
tested for DDAVP responsiveness. Potential explanatory variables
included in the model were: blood group, route of administration,
dose, lifetime lowest FVIII:C, age, pre-DDAVP
FVIII:C/VWF:Ag/VWF:Act, peak VWF:Ag/VWF:Act, and
DVWF:Ag. DVWF:Ag was defined as peak VWF:Ag minus pre-
DDAVP VWF:Ag. We restricted multivariate analyses to DDAVP
test results as only nine patients were exclusively treated with
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DDAVP (Figure 1). We added pre-DDAVP FVIII:C times age as an
interaction term to the model, as younger patients might have
lower pre-DDAVP FVIII:C and VWF:Ag levels, and pre-DDAVP
levels are known to affect the DDAVP response. A P-value <0.05
was considered statistically significant. Logistic transformation
was used for variables that were not-normally distributed. Missing
data were analyzed by Little’s missing completely at random
(MCAR) test. If Little’s MCAR test P-value was not significant,
missing data was imputed by multiple imputation.
Results
Baseline characteristics 
Eleven percent of the source population (n=169) had
moderate disease severity (Figure 1). 
Table 1 shows the baseline characteristics and response
rates of the 169 moderates with DDAVP. Administration
was mostly intravenous (62%). Patients with subcutaneous
versus intravenous administration were comparable, except
for weight (mean 76 kg intravenous and 52 kg subcuta-
neous, P<0.001). In total, 99 patients (59%) were responsive
to DDAVP (peak FVIII:C >20 IU/dL). The responses were
excellent, complete and partial in 25 (15%), 43 (25%), and
31 (18%) patients, respectively. Table 2A displays the
response rates per lowest lifetime FVIII and Table 2B shows
the discrepencies between lowest lifetime FVIIII and pre-
DDAVP FVIII. Further information on treatment outcomes
is displayed in Online Supplemental Table S1.
To address selection bias, we compared moderates that
received and did not receive DDAVP. The only characteris-
tic that differed between the groups was lifetime lowest
FVIII:C. This was higher in patients who received DDAVP
(median 4 (interquartile range [IQR] 3-5) vs. 3 (IQR 3-4)
IU/dL, P=0.002). Missing data are displayed in Online
Supplementary Table S2. 
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Table 1. Baseline characteristics and 1-Deamino-8-D-ArgininVasoPressin (desmopressin; DDAVP) response in moderate patients. 
All patients Inadequate Partial Complete Excellent
n=169 response response response response
<20 IU/dL 20-29 IU/dL 30-49 IU/dL ≥50 IU/dL
n=70 (41%) n=31 (18%) n=43 (25%) n=25 (15%)
Calendar year of birth, median (IQR) 1977 (1961-1991) 1975 (1960-1992) 1971 (1961-1990) 1979 (1959-1991) 1974 (1964-1990)
Age at DDAVP administration, 23 (12-41) 21 (8-43) 25 (17-35) 23 (9-49) 28 (16-41)
median years (IQR)
Lifetime lowest FVIII:C, 4 (3-5) 4 (2-5) 4 (3-5) 4 (3-5) 4 (3-5)
median IU/dL (IQR)
Pre-DDAVP FVIII:C, median IU/dL (IQR) 5 (4-9) 4 (3-5) 5 (4-6) 7 (5-12) 11 (8-17)
Pre-DDAVP VWF:Act, median IU/dL (IQR) 87 (63-110) 95 (82-113) 84 (62-112) 73 (44-132) 73 (60-98)
Pre-DDAVP VWF:Ag, median IU/dL (IQR) 93 (75-118) 103 (81-127) 93 (78-116) 96 (69-120) 76 (59-100)
Bloodgroup, n (%)
O 33 (20) 9 (13) 7 (23) 14 (33) 3 (12)
Non-O 33 (20) 14 (20) 9 (29) 5 (12) 5 (20)
Unknown 103 (61) 47 (67) 15 (48) 24 (56) 17 (68)
Weight, median kg (IQR) 75 (54-86) 72 (48-83) 72 (60-88) 76 (45-85) 77 (62-96)
BMI, median (IQR) 24 (19-27) 22 (19-27) 26 (19-29) 25 (17-26) 25 (18-27)
Total amount of DDAVP, median µg (IQR) 20 (16-24) 20 (14-24) 20 (18-24) 20 (14-24) 20 (19-29)
DDAVP dose per kg, median µg (IQR) 0.3 (0.29-0.31) 0.3 (0.30-0.32) 0.3 (0.30-0.31) 0.3 (0.25-0.31) 0.3 (0.29-0.30)
Route of administration
Intraveneous 104 (62) 33 (47) 19 (61) 32 (74) 20 (80)
Intranasal 9 (5) 3 (4) 3 (10) 1 (2) 2 (8)
Subcutaneous 56 (33) 34 (49) 9 (29) 10 (23) 3 (12)
Peak FVIII:C, median IU/dL (IQR) 24 (14-39) 13 (8-17) 24 (21-27) 36 (33-42) 63 (57-87)
Incremental response, median (IQR) 4 (2.7-6.3) 3 (2.1-4) 4.8 (3.9-6.5) 5.1 (3.4-8) 5,5 (4.4-8.7)
Time after DDAVP administration 60 (60-75) 60 (60-82) 60 (52-78) 60 (45-75) 60 (30-60)
for peak levels, median minutes (IQR)
Peak VWF:Act median IU/dL (IQR) 203 (186-260) 200 (192-234) 210 (137-260) 205 (118-326) 212 (178-284)
Peak VWF:Ag median IU/dL (IQR) 209 (188-257) 212 (188-267) 206 (184-215) 197 (153-216) 248 (184-371)
Test, n (%) 159 (94) 65 (93) 28 (90) 41 (95) 25 (100)
Treatment, n (%) 9 (5) 4 (6) 3 (10) 2 (5) 0
Mutation known, n (%) 106 (63) 40 (57) 17 (55) 31 (72) 18 (72)
*Interquartile Range (IQR). **Number. FVIII: factor VIII; VWF:Act: von Willebrand factor activity; VWF:Ag: von Willebrand factor antigen; BMI: body mass index. 
Side effects
Where data was available, side effects were present in
3/119 cases. Three patients reported skin flushing and one
patient had an abnormally low blood pressure (defined as
<2SD for age) with an increased heart rate (>100/min) fol-
lowing DDAVP administration. 
Univariate analyses of peak FVIII:C: no versus at least
complete response 
Complete and excellent responders had significantly
higher pre-DDAVP FVIII:C (P<0.001) and a higher propor-
tion of intravenous administration. Pre-DDAVP VWF
showed a trend towards lower levels in excellent respon-
ders (Ag: P=0.06, Act: P=0.07). No differences were
observed between the response groups for other character-
istics. 
Mutations
Genotype was known in 107 patients (63%). We identi-
fied 58 different mutations of which nine were present in at
least three patients (Table 3, Figure 2). The Arg2169His
mutation was most prevalent (n=21). Responses are scat-
tered among the different mutation groups.
Multivariate analysis of peak FVIII:C and increment
The following predictors explain 65% (Adjusted 
R2=0.65) of the variation in peak FVIII:C: intravenous
administration, pre-DDAVP FVIII:C and VWF:Ag,
DVWF:Ag, peak VWF:Act and age (Table 4A).
Both pre-FVIII:C and DVWF:Ag have strong effects; the
peak FVIII:C increases by 2.5 IU/dL for every unit increase
in pre-DDAVP FVIII:C, and by 0.165 IU/dL for every unit
increase in DVWF:Ag (DDAVP induced rise of VWF:Ag).
Peak FVIII:C increased with intravenous compared to sub-
cutaneous and intranasal administration (β=3.7).
Remarkably, for every unit increase in baseline VWF:Ag,
peak FVIII:C decreases by 0.117 IU/dL. 
The incremental response of FVIII:C can be explained for
29% (Adjusted R2=0.29) by DVWF:Ag, pre-DDAVP
VWF:Ag, lowest lifetime FVIII:C, and the interaction term
age*pre-DDAVP FVIII:C (Table 4B). For every unit increase
in D VWF:Ag, the incremental response increases by 0.047
IU/dL, whereas for every unit increase of pre-DDAVP
VWF:Ag, lifetime lowest FVIII:C, the interaction term, the
incremental response decreases by 0.026 IU/dL, 1.469
IU/dL, and 0.187 year*IU/dL, respectively.
Discussion
Herein, we present DDAVP response rates and predictors
in a large, international cohort of moderate HA patients. In
total, 68 patients (40%) achieved a peak FVIII:C of at least
30 IU/dL, among these 25 responses were excellent (FVIII:C
≥ 50IU/dL).
We identified six predictors of peak FVIII:C, which, taken
together, explain 65% of the variation in peak FVIII:C. The
pre-DDAVP FVIII:C and DDAVP-induced rise in VWF:Ag
were the most important. The incremental response could
be explained for 29% by different predictors, other than for
peak FVIII:C. 
Response rates
Eight single-center studies previously reported DDAVP
response rates in moderate HA patients and the character-
istics of included patients (Table 5).15-22 The number of mod-
erate patients in these studies varied from one to 17. 
Taken together, a total of 12 out of 56 patients from the
eight studies showed a response of at least 30 IU/dL after
DDAVP administration (21%). The difference between the
response rates that we report herein (40%) might be due to
differences in selection, population characteristics and
routes of administration. 
Predictors of peak FVIII:C
We identified six predictors explaining 65% of the varia-
tion in peak FVIII:C. 
Intravenous administration predicts higher peak FVIII:C
compared to subcutaneous or intranasal administration in
our cohort, as well as in other studies.17,24-31 However, it is
unknown, as of yet, whether this difference is clinically rel-
evant, and data on moderate patients are scarce.
Subcutaneous administration is believed to be biologically
equivalent to the intravenous route, but this is based on
only one paper.32 The rate of subcutaneous absorption
could affect either the FVIII:C peak or its timing. If there is
a clinically relevant difference, then this effect might be
more critical in moderate patients due to their lower base-
line levels. 
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Table 2A. Response rates per *Lowest lifetime factor VIII (FVIII:C).
FVIII:C (IU/dL)* Number of Inadequate Partial Complete Excellent % At least 
patients (%) Response Response Response Response comlete
1 7 (4) 6 0 0 1 14
2 16 (9) 12 2 2 0 13
3 43 (25) 16 7 14 6 47
4 47 (28) 15 10 12 10 47
5 56 (33) 21 12 15 8 41
Total 169 70 31 43 25
Table 2B. Pre-1-Deamino-8-D-ArgininVasoPressin (desmopressin; DDAVP) factor VIII (FVIII:C) minus lowest lifetime FVIII:C, per response group. 
All patients Inadequate Partial Complete Excellent
Pre-DDAVP FVIII:C-lowest lifetime 0 (0-4) 0 (0-0) 0 (0-1) 4 (0-8) 7 (3.5-13.5)
FVIII:C, median IU/dL (IQR)
IQR: interquartile range.
Our observation that higher pre-DDAVP FVIII:C predicts
higher peak FVIII:C in moderate HA patients is supported
by other studies.15,18 
DVWF:Ag was the second strongest predictor of peak
FVIII:C. In consistency with this finding, we identified
lower pre-DDAVP VWF:Ag as a predictor of peak FVIII:C.
We can only speculate on the biological mechanism
explaining this observation. Potentially, the stronger
increase in VWF provides more binding sites for FVIII
released upon DDAVP administration. Some patients may
have higher pre-DDAVP VWF:Ag due to stress. Stress is
known to increase endogenous FVIII:C and VWF. Hence,
patients may have already released some of their stored
VWF due to stress, with with less potential for VWF to rise
further with DDAVP. Finally, it is conceivable that some
patients have a phenotype of “greedy” endothelium,
whereby VWF stores (or storage compartments) are only
depleted upon extra (DDAVP) stimulation. There is still
more to learn about the exact sources and secretion of both
FVIII and VWF upon DDAVP stimulation, and how they
interact. 
It is important to stress that DVWF:Ag is derived from a
post hoc parameter (DDAVP-induced rise in VWF:Ag), and
can therefore not be used by the clinician to predict
response adequacy in advance.
We do not have an explanation for the lower peak
VWF:Act which predicts a higher FVIII:C peak. This finding
is inconsistent with the DVWF:Ag finding. 
Our finding that younger age predicted higher peak
FVIII:C in our cohort of moderate HA patients is inconsis-
tent with the literature reporting moderate patients. Stoof et
al. and Knöfler et al. did not find an effect of age on DDAVP
response, which they both attribute to the fact that the age
of their population was higher than in the studies of Seary
et al. and Revel-Vilk et al. (Table 5).15-18 Both Seary et al. and
Revel-Vilk et al. found that responders had a higher mean
age compared to non-responders, however, they did not
adjust for pre-DDAVP FVIII:C. Furthermore, their study
was performed exclusively in children whereas our study
focuses predominantly on adults (Table 5).15,18 
Determinants of incremental response
We identified four predictors of the incremental response;
DVWF:Ag, pre-DDAVP VWF:Ag and lifetime lowest
FVIII:C levels increase the incremental response.
Furthermore, a smaller product of the interaction term
age*pre-DDAVP FVIII:C predicted a higher incremental
response. The interaction term indicates that the effect of
pre-DDAVP FVIII:C on the incremental change of FVIII fol-
lowing DDAVP varies for age, or that the effect of age on
the incremental change of FVIII following DDAVP is altered
by pre-DDAVP FVIII:C.
This is the first study which used incremental response as
an outcome variable reflecting the biological mechanisms
underlying DDAVP response. Unlike for peak FVIII:C, for
incremental response the pre-DDAVP is not a predictor and
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Figure 1. Patient selection of 169
moderate hemophilia A (HA)
patients with 1-Deamino-8-D-
ArgininVasoPressin (desmopressin;
DDAVP) administration. The 169
patients are from 23 different hemo-
philia treatment centers. *Reason
for treatment was unknown for one
patient.
Table 3. Mutations in at least three patients.
Number of No Partial Complete Excellent
patients (%) Response Response Response Response
Pro149Arg 6 (4) 1 2 3 0
Tyr450Asn 3 (2) 3 0 0 0
Arg550Cys 3 (2) 0 1 1 1
Arg612Cys 3 (2) 0 0 1 2
Arg1960Gln 3 (2) 0 1 1 1
Gly1979Val 3 (2) 0 0 3 0
Arg2169His 21 (12) 2 3 11 5
Trp2248Cys 3 (2) 1 0 2 0
Gln2265Arg 3 (2) 1 1 0 1
Total 48 (28) 8 8 22 10
*Human Genome Variation Society nomenclature was used. Mutations in bold were additionally identified as high-risk mutations for inhibitor development. 
lifetime lowest FVIII:C is inversely associated. This is most
likely due to the reciprocal effect of higher pre-DDAVP
FVIII:C on the relative increase, since it is the denominator
of our outcome variable. There may be an effect of stress-
induced increase of FVIII, depicted in Table 2B by a differ-
ence between lowest lifetime and pre-DDAVP FVIII:C.
However, we did not adjust for age and mutation, as the
effect of age on FVIII:C is dependent on mutation.33
The variation in the incremental response was explained
for only 29% by the four identified predictors. This is less
than the explained variation in peak response (65%). We
believe that further analyses of different mutation groups
might help to reveal the observed discrepancy in explained
variance. 
Mutation analysis
Two studies presented the DDAVP response for different
mutations in non-severe patients.15,16 All moderate patients
DDAVP response in moderate hemophilia A 
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Figure 2. Mutations and associated response to 1-Deamino-8-D-
ArgininVasoPressin (desmopressin; DDAVP). All mutations were
present in three patients, except for the Pro149Arg and
Arg2169His mutation (n=6 and n=21, respectively). The size of
the diagrams reflects the number of patients. 
Table 4A. Multiple linear regression model of predictors of peak factor
VIII (FVIII:C) explaining 65% of peak FVIII:C. 
Unstandardized 95%Confidence 
β Interval
Coefficients
Intravenous administration 3.7 1.52 5.88
Pre-DDAVP FVIII:C (IU/dL) 2.51 2.33 2.7
DVWF:Ag (IU/dL) 0.17 0.15 0.18
Pre- DDAVP VWF:Ag (IU/dL) -0.12 -0.14 -0.09
Peak VWF:Act (IU/dL) -0.03 -0.04 -0.01
Age (log, in yrs)* -2.74 -5.02 -0.46
*All predictors had a P-value <0.001, except for that of age (P=0.019). Peak FVIII:C
increases 2.5 IU/dL for every unit increase in pre-1-Deamino-8-D-ArgininVasoPressin
(desmopressin; DDAVP) FVIII:C and 0.165 IU/dL for every unit increase in D von
Willebrand factor antigen (VWF:Ag). In comparison to subcutaneous or intranasal
administration, the response after intravenous administration appears to be 3.7-fold
higher, although this is not statistically significant due to low patient numbers. For
every unit increase in baseline VWF:Ag, peak von Willebrand factor activity
(VWF:Act) and age, peak FVIII:C decreases by 0.12 IU/dL, 0.03 IU/dL and 2.74 log
years, respectively.
Table 4B. Multiple linear regression model of incremental response
(peak factor VIII [FVIII:C]/pre-1-Deamino-8-D-ArgininVasoPressin
[desmopressin; DDAVP] FVIII:C) explaining 29% of incremental
response. 
Unstandardized 95% Confidence 
β Interval 
Coefficients
DVWF:Ag (IU/dL) 0.05 0.04 0.05
Pre-DDAVP VWF:Ag (IU/dL) -0.03 -0.04 -0.15
Lifetime lowest FVIII:C (IU/dL) -1.47 -1.87 -1.07
Interaction term -0.19 -0.25 -0.13
(age*pre-DDAVP FVIII:C)
*All predictors had a P-value <0.001. For every unit increase in D von Willebrand fac-
tor antigen (VWF:Ag), the incremental response increases by 0.047 IU/dL, whereas for
every unit increase of pre-DDAVP VWF:Ag, lifetime lowest FVIII:C, and the interaction
term, incremental response decreases by 0.026 IU/dL, 1.469 IU/dL, and 0.187
year*IU/dL, respectively.
from these studies are also included in our cohort.
Unexpectedly, we observed a discordance in DDAVP
response among patients with the same mutation that was
not due to differences in route of administration (Figure 2).
Four mutations present in at least three patients were also
identified in the INSIGHT cohort as high-risk mutations for
inhibitor development (Arg550Cys, Arg612Cys,
Arg2150His and Trp2248Cys HGVS numbering).23 As
Figure 2 and Table 3 show, half of the patients with these
mutations in our cohort showed at least a complete
response to DDAVP. This is of clinical importance as these
patients may be successfully treated with DDAVP in order
to reduce hazardous exposure to FVIII concentrates.
Limitations and strengths
This large, international cohort study provides data on
the response to DDAVP in moderate HA patients. Our
study is unique owing to the large number of patients
included, thus increasing the statistical power. 
As lifetime lowest and pre-DDAVP FVIII:C was not
measured in a standardized manner, this may have led to an
overestimation of patients who were once classified as
moderate, but who were not defined as moderate at the
time of the DDAVP test. This can be seen in Table 1, where
patients with complete and excellent responses have a
higher pre-DDAVP FVIII:C irrespective of their lowest life-
time FVIII:C. 
With respect to our outcome variables, it is important to
state that the biological response is only a proxy of the clin-
ical response to DDAVP. Additional data are warranted to
establish when and to which extent desmopressin can be
clinically used to treat patients with moderate HA.
As only 32% of the moderate patients from our source
population were tested or treated with DDAVP, this might
lead to an overestimation of patients with a good response.
The proportion of moderate patients receiving DDAVP per
hemophilia treatment center ranged from 19 to 50.
Moderate patients who received DDAVP had higher lowest
lifetime FVIII:C compared to those who did not. For these
reasons, caution is needed when extrapolating these results
to all moderate HA patients. 
Although our study is unique in terms of its size, we still
lacked the power to further analyze the effect of mutations
on DDAVP response in moderate HA patients. As the F8
genotype is known to influence baseline FVIII:C, and there-
by DDAVP response, the effect of mutations via baseline
FVIII:C may contribute to clarifying 35% of the unex-
plained variation in peak FVIII:C levels.33
For further functional analyses of genotype, it would
have been informative to have, in addition, the FVIII anti-
gen (FVIII:Ag) levels. Castaman et al. demonstrated that the
presence of a dysfunctional FVIII molecule
(Antigen>Activity) per se does not prevent a response to
DDAVP.34 
J.I. Loomans et al.
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Table 5. Previous studies on 1-Deamino-8-D-ArgininVasoPressin (desmopressin; DDAVP) response in moderate hemophilia A (HA) patients. 
Author, year N Study Intervention Age Investigated DDAVP dose Time FVIII:C Pre-DDAVP After Partial At least
design (median determinants (μg/kg) and measurement FVIII:C DDAVP response complete
years, IQR) of DDAVP administration (min) (IU/dL) FVIII:C response
responseƗ route (IU/dL)
Stoof et al. 17 Retro- Test 28 Blood group O, IV and IN 0; 60; 180; 600 1-5* uk uk 8 (47%)
2014 spective and (8–67)* mutations, age,
treatment route of
administration
Knöfler et al. 2 Retro- Test 32.5 Age, 0.4 IV and 0; 30; 60; 2.6 14.75 0 0
2012 spective (16.7–48.2) administration 0.4 SC 120; 240 (1.7–3.5) (14– 15.5)
route
Seary et al. 13 Retro- Test < 18 Age, 0.3 IV 0; 60; 240 1-5 * uk 0 1 (8%)
2012 spective and treatment disease severity, and
mutations 0.3 SC
Revel-Vilk et al. 11 Retro- Test 2.8 Age, disease 0.3 IV 0; 60 1-5 * uk 0 0
2002 spective (0.13–9.75)** severity, 
blood group O
Ghirardini et al. 2 Prospective Treatment uk uk 0.3 SC 0; 60 3.5 11.5 0 0
1988 (3–4) (9–14)
De La Fuente 8 Prospective Test and 30 uk 0.3 IV 0; 15; 30; 60; 3.5 24 2 3
et al. 1985 treatment (2–66) 180; 300; 1440 (2–5) (7–47) (25%) (38%)
Mariana et al. 2 Prospective Treatment uk uk 0.3 IV 0; 60 4.8 15.7 1 0
1984 and 0.4 IV (4.5–5) (11.3–20) (50%)
Warrier et al. 1 Prospective Test and 23 Administration 2.0 IN 0; 15; 90; 180; 270 2 13 0 0
1983 treatment (10–45)*** route
Total 56 3 (5%) 12 (21%)
ƗUnderlined factors were identified determinants. *Age is not specific for moderate patients, but for complete study population including mild HA patients. **Age is not specific
for moderate HA patients, but for non-responders. ***Age is not specific for moderate HA patients, but for all patients with IN administration of DDAVP. IV: intravenous; IN:
intranasal; SC: subcutaneous; uk: unknown; IQR: interquartile range; FVIII:C: factor VIII.
Clinical significance and future studies
As illustrated in Table 5, the use of DDAVP for moderate
HA patients in clinical practice has been limited to a few
cases over the last 40 years, despite the fact that this drug
has been available since 1977. The study herein evinces that
40% of the patients with moderate HA in our cohort have
a clinical relevant response to DDAVP for mild
bleeds/injuries. Moreover, half of the patients with high
inhibitor risk mutations respond to DDAVP; for this reason,
it is important to always assess such patients for DDAVP
responsiveness. Doing so might lead to less exposure to
FVIII concentrates, which reduces risk for inhibitor devel-
opment, and realizes a reduction in costs. 
In order to confirm our findings, future studies should
focus on the prospective inclusion of moderate HA patients.
Lastly, more data on mutations are needed in order to assess
the effect of F8missense mutations on DDAVP response in
these patients. 
Conclusion
In 40% of the administrations in moderate HA patients in
our cohort, the use of DDAVP is adequate for treatment in
case of minor bleeding or trauma; as such, it is important to
consistently assess moderate patients for DDAVP respon-
siveness. 
Furthermore, we identified six predictors of peak FVIII:C,
which, taken together, explain 65% of the variation in peak
FVIII:C. Pre-DDAVP FVIII:C levels and the patients’ ability
to raise VWF levels are the essential predictors for response.
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